Follow
James McCabe
James McCabe
Verified email at astrazeneca.com
Title
Cited by
Cited by
Year
Virtual cocrystal screening
D Musumeci, CA Hunter, R Prohens, S Scuderi, JF McCabe
Chemical Science 2 (5), 883-890, 2011
3012011
Synthesis and recognition properties of aromatic amide oligomers: molecular zippers
AP Bisson, FJ Carver, DS Eggleston, RC Haltiwanger, CA Hunter, ...
Journal of the American Chemical Society 122 (37), 8856-8868, 2000
1832000
Substituent effects on edge‐to‐face aromatic interactions
FJ Carver, CA Hunter, DJ Livingstone, JF McCabe, EM Seward
Chemistry–A European Journal 8 (13), 2847-2859, 2002
1532002
Effect of moisture on polyvinylpyrrolidone in accelerated stability testing
S Fitzpatrick, JF McCabe, CR Petts, SW Booth
International Journal of Pharmaceutics 246 (1-2), 143-151, 2002
1452002
Validation of a computational cocrystal prediction tool: comparison of virtual and experimental cocrystal screening results
T Grecu, CA Hunter, EJ Gardiner, JF McCabe
Crystal growth & design 14 (1), 165-171, 2014
1272014
A 1H NMR study of crystal nucleation in solution
A Spitaleri, CA Hunter, JF McCabe, MJ Packer, SL Cockroft
CrystEngComm 6 (80), 489-493, 2004
932004
Solvent effects of the structures of prenucleation aggregates of carbamazepine
CA Hunter, JF McCabe, A Spitaleri
CrystEngComm 14 (21), 7115-7117, 2012
742012
Quantitative measurements of edge‐to‐face aromatic interactions by using chemical double‐mutant cycles
FJ Carver, CA Hunter, PS Jones, DJ Livingstone, JF McCabe, EM Seward, ...
Chemistry–A European Journal 7 (22), 4854-4862, 2001
672001
Virtual screening identifies new cocrystals of nalidixic acid
T Grecu, H Adams, CA Hunter, JF McCabe, A Portell, R Prohens
Crystal growth & design 14 (4), 1749-1755, 2014
642014
Long-term amorphous drug stability predictions using easily calculated, predicted, and measured parameters
K Nurzyńska, J Booth, CJ Roberts, J McCabe, I Dryden, PM Fischer
Molecular pharmaceutics 12 (9), 3389-3398, 2015
572015
Biodegradable hybrid block copolymer–lipid vesicles as potential drug delivery systems
S Khan, J McCabe, K Hill, PA Beales
Journal of colloid and interface science 562, 418-428, 2020
562020
Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of nonsmall cell lung cancer …
RA Ward, MJ Anderton, P Bethel, J Breed, C Cook, EJ Davies, A Dobson, ...
Journal of medicinal chemistry 62 (24), 11004-11018, 2019
482019
Solvent effects on acridine polymorphism
D Musumeci, CA Hunter, JF McCabe
Crystal growth & design 10 (4), 1661-1664, 2010
442010
Cocrystals of spironolactone and griseofulvin based on an in silico screening method
T Grecu, R Prohens, JF McCabe, EJ Carrington, JS Wright, L Brammer, ...
CrystEngComm 19 (26), 3592-3599, 2017
432017
Structural characterisation of amorphous solid dispersions via metropolis matrix factorisation of pair distribution function data
HS Geddes, H Blade, JF McCabe, LP Hughes, AL Goodwin
Chemical Communications 55 (89), 13346-13349, 2019
412019
Quinazoline derivatives
RH Bradbury, JG Kettle, J McCabe, A Turner, LFA Hennequin
US Patent 7,148,230, 2006
412006
How strong is a π-facial hydrogen bond?
H Adams, KDM Harris, GA Hembury, CA Hunter, D Livingstone, ...
Chemical Communications, 2531-2532, 1996
361996
Quinazoline derivatives
R Bradbury, J Kettle, J McCabe, A Turner, L Hennequin
US Patent App. 11/636,549, 2007
322007
Crystallization from volatile deep eutectic solvents
J Potticary, C Hall, V Hamilton, JF McCabe, SR Hall
Crystal Growth & Design 20 (5), 2877-2884, 2020
252020
Monitoring dehydration kinetics using simultaneous thermal and spectral methods
MA Beard, OR Ghita, J McCabe, KE Evans
Journal of Raman Spectroscopy 41 (10), 1283-1288, 2010
192010
The system can't perform the operation now. Try again later.
Articles 1–20